A review of the clinical pharmacology of maraviroc. Introduction.
Boffito
Marta
M
St Stephens Aids Trust, Crusaid Research Institute, St Stephen's Centre, London, UK. marta.boffito@chelwest.nhs.uk
Abel
Samantha
S
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000077592:Maraviroc; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc